NCT03874247

Brief Summary

A randomized, double-blind, placebo-controlled, parallel, multi-center phase III clinical trial

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
94

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2019

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 25, 2019

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

March 12, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 14, 2019

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

March 19, 2019

Status Verified

March 1, 2019

Enrollment Period

10 months

First QC Date

March 12, 2019

Last Update Submit

March 17, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • SPID-D3

    Sum of Pain Intensity Differences(100 mm pain VAS)

    Day 3

Study Arms (2)

Pelubiprofen

EXPERIMENTAL
Drug: pelubiprofen 45mg

Pelubiprofen placebo

PLACEBO COMPARATOR
Drug: pelubiprofen placebo

Interventions

bid for 3 days after meal

Pelubiprofen

bid for 3 days after meal

Pelubiprofen placebo

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patient, ages over 19 years
  • Patients with post traumatic acute pain within 48 hr(sprain/strain)
  • Patient whose pain scale is over 50 mm(VAS score)

You may not qualify if:

  • Patients with chronic pain
  • Presence of a fracture or more than one injury
  • Previous adverse reaction or known allergy to NSAIDs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, Seodaemun-gu, South Korea

RECRUITING

MeSH Terms

Interventions

pelubiprofen

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double-blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2019

First Posted

March 14, 2019

Study Start

February 25, 2019

Primary Completion

December 31, 2019

Study Completion

December 31, 2019

Last Updated

March 19, 2019

Record last verified: 2019-03

Locations